Amgen (NASDAQ: AMGN) has announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million. The acquisition adds to Amgen’s portfolio an investigational small molecule that targets and degrades two proteins (MLLT1/3) that drive specific types of acute myeloid leukemia (AML), a fast-growing blood cancer.
Read the full article: Amgen Acquires Dark Blue Therapeutics, Bolstering Oncology Pipeline //
Source: https://www.prnewswire.com/news-releases/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline-302652998.html